查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1866595

結核病疫苗治療：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Tuberculosis Vaccine Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 123 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024年全球結核病疫苗治療市場規模估計為 8,042萬美元，預計到2031年將達到 9,800萬美元，在預測期（2025-2031年）內以 2.9%的年複合成長率成長。

本報告對近期結核病疫苗治療的關稅調整和國際策略措施進行了全面評估，包括跨境產業佈局、資本配置模式、區域經濟相互依存關係和供應鏈重組。

結核病疫苗主要用於預防結核病（TB），嚴重的感染疾病，可影響肺部以及身體其他部位，包括骨骼、關節和腎臟。卡介苗（BCG）疫苗已有80年的歷史，目前是使用最廣泛的疫苗之一。在設有國家兒童免疫規劃的國家，超過80%的新生兒和嬰兒接種了疫苗。此外，卡介苗也用於治療某些類型的膀胱癌，膀胱癌的特徵是膀胱壁黏膜內異常或癌症細胞的增殖。卡介苗可以預防膀胱癌復發，並降低侵襲性癌症的風險。2024年，全球結核病疫苗的產量約為3.18億劑，全球平均市場價格約為每劑0.21美元。

全球結核病負擔依然沉重，世界衛生組織報告每年新增病例超過1000萬例，主要集中在亞洲和非洲，使得結核病疫苗的需求強勁。各國政府實施疫苗接種計畫和公共衛生政策，透過政策和財政獎勵，支持提高疫苗接種覆蓋率，並促進新疫苗的研發。主要疫苗生產商的年度報告證實，持續的研發投入、不斷擴大的產能和出口量，並支撐著全球市場的穩定成長。證券調查顯示，對多重抗藥性結核病（MDR-TB）預防的需求以及新型可追溯疫苗管理系統的引進，將進一步促進疫苗在公共衛生和臨床預防領域的應用。

結核病疫苗的研發和生產面臨許多挑戰，包括技術複雜性、漫長的臨床試驗週期以及嚴格的監管核准。年度報告強調，原料供應、低溫運輸物流和儲存要求對成本和供應穩定性提出了很高的要求。在某些地區，公共衛生資源匱乏、病患依從性差以及疫苗可近性不足限制了疫苗接種率，而政策調整、價格管制和醫保償付範圍的變化可能會影響市場收入。國際法規和核准要求的差異也增加了海外市場擴張的不確定性。

下游需求擴展，涵蓋全人群和生命週期的疫苗接種和免疫管理。雖然新生兒和兒童仍然是核心目標族群，但保護高風險成年人的需求日益成長。數位化疫苗管理和遠端監測平台能夠實現疫苗接種的全程追蹤，提高依從性和療效評估。根據中期報告，新型多重抗藥性結核病（MDR-TB）疫苗和能夠監測免疫反應的產品將成為關鍵的差異化因素，而與數位化管理和政策獎勵的整合有望在公共衛生和個人化疾病預防領域創造長期市場價值。

本報告目的是依地區/國家、類型和應用對全球結核病疫苗治療市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

結核病疫苗治療市場規模、估算和預測以銷售量（千劑）和收入（百萬美元）為單位呈現，基準年為2024年，並包含2020年至2031年的歷史資料和預測資料。報告採用定量和定性分析相結合的方法，幫助讀者制定業務/成長策略、評估市場競爭、分析自身在當前市場中的地位，並就結核病疫苗治療做出明智的商業決策。

市場區隔

公司

  • Merck
  • Japan BCG Lab
  • Serum Institute of India
  • AJ Vaccines
  • BioFarma
  • GreenSignal Bio Pharma
  • China National Biotec
  • Biomed Lublin
  • Taj Pharmaceuticals
  • Ataulpho de Paiva
  • IVAC
  • Queen Saovabha Mem. Inst
  • Microgen

依類型

  • 免疫疫苗
  • 治療性疫苗

依應用

  • 自籌資金
  • 聯合國兒童基金會
  • 其他

依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Tuberculosis Vaccine Treatment was estimated to be worth US$ 80.42 million in 2024 and is forecast to a readjusted size of US$ 98 million by 2031 with a CAGR of 2.9% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Tuberculosis Vaccine Treatment cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guerin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme. Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.In 2024, global Tuberculosis Vaccine Treatment production reached approximately 318 m units, with an average global market price of around US$ 0.21 perunit

The global TB burden remains high, with WHO reporting over 10 million new cases annually, concentrated mainly in Asia and Africa, providing strong demand for tuberculosis vaccines. Governments are implementing immunization programs and public health policies to increase vaccination coverage and support new vaccine R&D through policy and funding incentives. Annual reports of leading vaccine manufacturers show sustained R&D investment, capacity expansion, and export growth, maintaining steady global market expansion. Brokerage research indicates that the need for multidrug-resistant TB (MDR-TB) prevention and new trackable vaccine management systems will further enhance vaccine penetration in public health and clinical prevention.

Tuberculosis vaccine R&D and manufacturing face challenges such as technical complexity, long clinical trial cycles, and strict regulatory approvals. Annual reports highlight that raw material supply, cold-chain logistics, and storage requirements impose high demands on cost and supply stability. Vaccination coverage in some regions is limited by insufficient public health resources, patient adherence, and vaccine accessibility, while policy adjustments, price controls, and reimbursement coverage changes may affect market revenue. Differing international regulations and approval requirements increase uncertainties for overseas market expansion.

Downstream demand is extending toward full-population and lifecycle vaccination and immunization management. Newborns and children remain the core target population, while high-risk adult protection needs are growing. Digital vaccine management and remote monitoring platforms facilitate end-to-end tracking of vaccine administration, improving adherence and efficacy evaluation. Brokerage reports suggest that new MDR-TB vaccines and products with monitorable immune responses will be key differentiation points, while integration with digital management and policy incentives is expected to create long-term market value in public health and individual disease prevention.

This report aims to provide a comprehensive presentation of the global market for Tuberculosis Vaccine Treatment, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Tuberculosis Vaccine Treatment by region & country, by Type, and by Application.

The Tuberculosis Vaccine Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tuberculosis Vaccine Treatment.

Market Segmentation

By Company

  • Merck
  • Japan BCG Lab
  • Serum Institute of India
  • AJ Vaccines
  • BioFarma
  • GreenSignal Bio Pharma
  • China National Biotec
  • Biomed Lublin
  • Taj Pharmaceuticals
  • Ataulpho de Paiva
  • IVAC
  • Queen Saovabha Mem. Inst
  • Microgen

Segment by Type

  • Immune Vaccine
  • Therapy Vaccine

Segment by Application

  • Self-Procurement
  • UNICEF
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Tuberculosis Vaccine Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Tuberculosis Vaccine Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Tuberculosis Vaccine Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Tuberculosis Vaccine Treatment Product Introduction
  • 1.2 Global Tuberculosis Vaccine Treatment Market Size Forecast
    • 1.2.1 Global Tuberculosis Vaccine Treatment Sales Value (2020-2031)
    • 1.2.2 Global Tuberculosis Vaccine Treatment Sales Volume (2020-2031)
    • 1.2.3 Global Tuberculosis Vaccine Treatment Sales Price (2020-2031)
  • 1.3 Tuberculosis Vaccine Treatment Market Trends & Drivers
    • 1.3.1 Tuberculosis Vaccine Treatment Industry Trends
    • 1.3.2 Tuberculosis Vaccine Treatment Market Drivers & Opportunity
    • 1.3.3 Tuberculosis Vaccine Treatment Market Challenges
    • 1.3.4 Tuberculosis Vaccine Treatment Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Tuberculosis Vaccine Treatment Players Revenue Ranking (2024)
  • 2.2 Global Tuberculosis Vaccine Treatment Revenue by Company (2020-2025)
  • 2.3 Global Tuberculosis Vaccine Treatment Players Sales Volume Ranking (2024)
  • 2.4 Global Tuberculosis Vaccine Treatment Sales Volume by Company Players (2020-2025)
  • 2.5 Global Tuberculosis Vaccine Treatment Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Tuberculosis Vaccine Treatment Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Tuberculosis Vaccine Treatment Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Tuberculosis Vaccine Treatment
  • 2.9 Tuberculosis Vaccine Treatment Market Competitive Analysis
    • 2.9.1 Tuberculosis Vaccine Treatment Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Tuberculosis Vaccine Treatment Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tuberculosis Vaccine Treatment as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Immune Vaccine
    • 3.1.2 Therapy Vaccine
  • 3.2 Global Tuberculosis Vaccine Treatment Sales Value by Type
    • 3.2.1 Global Tuberculosis Vaccine Treatment Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Tuberculosis Vaccine Treatment Sales Value, by Type (2020-2031)
    • 3.2.3 Global Tuberculosis Vaccine Treatment Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Tuberculosis Vaccine Treatment Sales Volume by Type
    • 3.3.1 Global Tuberculosis Vaccine Treatment Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Tuberculosis Vaccine Treatment Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Tuberculosis Vaccine Treatment Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Tuberculosis Vaccine Treatment Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Self-Procurement
    • 4.1.2 UNICEF
    • 4.1.3 Other
  • 4.2 Global Tuberculosis Vaccine Treatment Sales Value by Application
    • 4.2.1 Global Tuberculosis Vaccine Treatment Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Tuberculosis Vaccine Treatment Sales Value, by Application (2020-2031)
    • 4.2.3 Global Tuberculosis Vaccine Treatment Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Tuberculosis Vaccine Treatment Sales Volume by Application
    • 4.3.1 Global Tuberculosis Vaccine Treatment Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Tuberculosis Vaccine Treatment Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Tuberculosis Vaccine Treatment Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Tuberculosis Vaccine Treatment Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Tuberculosis Vaccine Treatment Sales Value by Region
    • 5.1.1 Global Tuberculosis Vaccine Treatment Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Tuberculosis Vaccine Treatment Sales Value by Region (2020-2025)
    • 5.1.3 Global Tuberculosis Vaccine Treatment Sales Value by Region (2026-2031)
    • 5.1.4 Global Tuberculosis Vaccine Treatment Sales Value by Region (%), (2020-2031)
  • 5.2 Global Tuberculosis Vaccine Treatment Sales Volume by Region
    • 5.2.1 Global Tuberculosis Vaccine Treatment Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Tuberculosis Vaccine Treatment Sales Volume by Region (2020-2025)
    • 5.2.3 Global Tuberculosis Vaccine Treatment Sales Volume by Region (2026-2031)
    • 5.2.4 Global Tuberculosis Vaccine Treatment Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Tuberculosis Vaccine Treatment Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 5.4.2 North America Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 5.5.2 Europe Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Tuberculosis Vaccine Treatment Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 5.7.2 South America Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Tuberculosis Vaccine Treatment Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 6.3.2 United States Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 6.4.2 Europe Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 6.5.2 China Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 6.6.2 Japan Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 6.7.2 South Korea Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Tuberculosis Vaccine Treatment Sales Value, 2020-2031
    • 6.9.2 India Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Tuberculosis Vaccine Treatment Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Merck
    • 7.1.1 Merck Company Information
    • 7.1.2 Merck Introduction and Business Overview
    • 7.1.3 Merck Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Merck Tuberculosis Vaccine Treatment Product Offerings
    • 7.1.5 Merck Recent Development
  • 7.2 Japan BCG Lab
    • 7.2.1 Japan BCG Lab Company Information
    • 7.2.2 Japan BCG Lab Introduction and Business Overview
    • 7.2.3 Japan BCG Lab Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Japan BCG Lab Tuberculosis Vaccine Treatment Product Offerings
    • 7.2.5 Japan BCG Lab Recent Development
  • 7.3 Serum Institute of India
    • 7.3.1 Serum Institute of India Company Information
    • 7.3.2 Serum Institute of India Introduction and Business Overview
    • 7.3.3 Serum Institute of India Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Serum Institute of India Tuberculosis Vaccine Treatment Product Offerings
    • 7.3.5 Serum Institute of India Recent Development
  • 7.4 AJ Vaccines
    • 7.4.1 AJ Vaccines Company Information
    • 7.4.2 AJ Vaccines Introduction and Business Overview
    • 7.4.3 AJ Vaccines Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 AJ Vaccines Tuberculosis Vaccine Treatment Product Offerings
    • 7.4.5 AJ Vaccines Recent Development
  • 7.5 BioFarma
    • 7.5.1 BioFarma Company Information
    • 7.5.2 BioFarma Introduction and Business Overview
    • 7.5.3 BioFarma Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 BioFarma Tuberculosis Vaccine Treatment Product Offerings
    • 7.5.5 BioFarma Recent Development
  • 7.6 GreenSignal Bio Pharma
    • 7.6.1 GreenSignal Bio Pharma Company Information
    • 7.6.2 GreenSignal Bio Pharma Introduction and Business Overview
    • 7.6.3 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Product Offerings
    • 7.6.5 GreenSignal Bio Pharma Recent Development
  • 7.7 China National Biotec
    • 7.7.1 China National Biotec Company Information
    • 7.7.2 China National Biotec Introduction and Business Overview
    • 7.7.3 China National Biotec Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 China National Biotec Tuberculosis Vaccine Treatment Product Offerings
    • 7.7.5 China National Biotec Recent Development
  • 7.8 Biomed Lublin
    • 7.8.1 Biomed Lublin Company Information
    • 7.8.2 Biomed Lublin Introduction and Business Overview
    • 7.8.3 Biomed Lublin Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Biomed Lublin Tuberculosis Vaccine Treatment Product Offerings
    • 7.8.5 Biomed Lublin Recent Development
  • 7.9 Taj Pharmaceuticals
    • 7.9.1 Taj Pharmaceuticals Company Information
    • 7.9.2 Taj Pharmaceuticals Introduction and Business Overview
    • 7.9.3 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Product Offerings
    • 7.9.5 Taj Pharmaceuticals Recent Development
  • 7.10 Ataulpho de Paiva
    • 7.10.1 Ataulpho de Paiva Company Information
    • 7.10.2 Ataulpho de Paiva Introduction and Business Overview
    • 7.10.3 Ataulpho de Paiva Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Ataulpho de Paiva Tuberculosis Vaccine Treatment Product Offerings
    • 7.10.5 Ataulpho de Paiva Recent Development
  • 7.11 IVAC
    • 7.11.1 IVAC Company Information
    • 7.11.2 IVAC Introduction and Business Overview
    • 7.11.3 IVAC Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 IVAC Tuberculosis Vaccine Treatment Product Offerings
    • 7.11.5 IVAC Recent Development
  • 7.12 Queen Saovabha Mem. Inst
    • 7.12.1 Queen Saovabha Mem. Inst Company Information
    • 7.12.2 Queen Saovabha Mem. Inst Introduction and Business Overview
    • 7.12.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Product Offerings
    • 7.12.5 Queen Saovabha Mem. Inst Recent Development
  • 7.13 Microgen
    • 7.13.1 Microgen Company Information
    • 7.13.2 Microgen Introduction and Business Overview
    • 7.13.3 Microgen Tuberculosis Vaccine Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.13.4 Microgen Tuberculosis Vaccine Treatment Product Offerings
    • 7.13.5 Microgen Recent Development

8 Industry Chain Analysis

  • 8.1 Tuberculosis Vaccine Treatment Industrial Chain
  • 8.2 Tuberculosis Vaccine Treatment Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Tuberculosis Vaccine Treatment Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Tuberculosis Vaccine Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Tuberculosis Vaccine Treatment Market Trends
  • Table 2. Tuberculosis Vaccine Treatment Market Drivers & Opportunity
  • Table 3. Tuberculosis Vaccine Treatment Market Challenges
  • Table 4. Tuberculosis Vaccine Treatment Market Restraints
  • Table 5. Global Tuberculosis Vaccine Treatment Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Tuberculosis Vaccine Treatment Revenue Market Share by Company (2020-2025)
  • Table 7. Global Tuberculosis Vaccine Treatment Sales Volume by Company (2020-2025) & (K Dose)
  • Table 8. Global Tuberculosis Vaccine Treatment Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Tuberculosis Vaccine Treatment Price by Company (2020-2025) & (USD/K Dose)
  • Table 10. Key Manufacturers Tuberculosis Vaccine Treatment Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Tuberculosis Vaccine Treatment Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Tuberculosis Vaccine Treatment
  • Table 13. Global Tuberculosis Vaccine Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tuberculosis Vaccine Treatment as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Tuberculosis Vaccine Treatment Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Tuberculosis Vaccine Treatment Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Tuberculosis Vaccine Treatment Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Tuberculosis Vaccine Treatment Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Tuberculosis Vaccine Treatment Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Tuberculosis Vaccine Treatment Sales Volume by Type: 2020 VS 2024 VS 2031 (K Dose)
  • Table 22. Global Tuberculosis Vaccine Treatment Sales Volume by Type (2020-2025) & (K Dose)
  • Table 23. Global Tuberculosis Vaccine Treatment Sales Volume by Type (2026-2031) & (K Dose)
  • Table 24. Global Tuberculosis Vaccine Treatment Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Tuberculosis Vaccine Treatment Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Tuberculosis Vaccine Treatment Price by Type (2020-2025) & (USD/K Dose)
  • Table 27. Global Tuberculosis Vaccine Treatment Price by Type (2026-2031) & (USD/K Dose)
  • Table 28. Global Tuberculosis Vaccine Treatment Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Tuberculosis Vaccine Treatment Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Tuberculosis Vaccine Treatment Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Tuberculosis Vaccine Treatment Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Tuberculosis Vaccine Treatment Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Tuberculosis Vaccine Treatment Sales Volume by Application: 2020 VS 2024 VS 2031 (K Dose)
  • Table 34. Global Tuberculosis Vaccine Treatment Sales Volume by Application (2020-2025) & (K Dose)
  • Table 35. Global Tuberculosis Vaccine Treatment Sales Volume by Application (2026-2031) & (K Dose)
  • Table 36. Global Tuberculosis Vaccine Treatment Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Tuberculosis Vaccine Treatment Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Tuberculosis Vaccine Treatment Price by Application (2020-2025) & (USD/K Dose)
  • Table 39. Global Tuberculosis Vaccine Treatment Price by Application (2026-2031) & (USD/K Dose)
  • Table 40. Global Tuberculosis Vaccine Treatment Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Tuberculosis Vaccine Treatment Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Tuberculosis Vaccine Treatment Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Tuberculosis Vaccine Treatment Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Tuberculosis Vaccine Treatment Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Tuberculosis Vaccine Treatment Sales Volume by Region (K Dose): 2020 VS 2024 VS 2031
  • Table 46. Global Tuberculosis Vaccine Treatment Sales Volume by Region (2020-2025) & (K Dose)
  • Table 47. Global Tuberculosis Vaccine Treatment Sales Volume by Region (2026-2031) & (K Dose)
  • Table 48. Global Tuberculosis Vaccine Treatment Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Tuberculosis Vaccine Treatment Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Tuberculosis Vaccine Treatment Average Price by Region (2020-2025) & (USD/K Dose)
  • Table 51. Global Tuberculosis Vaccine Treatment Average Price by Region (2026-2031) & (USD/K Dose)
  • Table 52. Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Tuberculosis Vaccine Treatment Sales Volume, (2020-2025) & (K Dose)
  • Table 56. Key Countries/Regions Tuberculosis Vaccine Treatment Sales Volume, (2026-2031) & (K Dose)
  • Table 57. Merck Company Information
  • Table 58. Merck Introduction and Business Overview
  • Table 59. Merck Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 60. Merck Tuberculosis Vaccine Treatment Product Offerings
  • Table 61. Merck Recent Development
  • Table 62. Japan BCG Lab Company Information
  • Table 63. Japan BCG Lab Introduction and Business Overview
  • Table 64. Japan BCG Lab Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 65. Japan BCG Lab Tuberculosis Vaccine Treatment Product Offerings
  • Table 66. Japan BCG Lab Recent Development
  • Table 67. Serum Institute of India Company Information
  • Table 68. Serum Institute of India Introduction and Business Overview
  • Table 69. Serum Institute of India Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 70. Serum Institute of India Tuberculosis Vaccine Treatment Product Offerings
  • Table 71. Serum Institute of India Recent Development
  • Table 72. AJ Vaccines Company Information
  • Table 73. AJ Vaccines Introduction and Business Overview
  • Table 74. AJ Vaccines Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 75. AJ Vaccines Tuberculosis Vaccine Treatment Product Offerings
  • Table 76. AJ Vaccines Recent Development
  • Table 77. BioFarma Company Information
  • Table 78. BioFarma Introduction and Business Overview
  • Table 79. BioFarma Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 80. BioFarma Tuberculosis Vaccine Treatment Product Offerings
  • Table 81. BioFarma Recent Development
  • Table 82. GreenSignal Bio Pharma Company Information
  • Table 83. GreenSignal Bio Pharma Introduction and Business Overview
  • Table 84. GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 85. GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Product Offerings
  • Table 86. GreenSignal Bio Pharma Recent Development
  • Table 87. China National Biotec Company Information
  • Table 88. China National Biotec Introduction and Business Overview
  • Table 89. China National Biotec Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 90. China National Biotec Tuberculosis Vaccine Treatment Product Offerings
  • Table 91. China National Biotec Recent Development
  • Table 92. Biomed Lublin Company Information
  • Table 93. Biomed Lublin Introduction and Business Overview
  • Table 94. Biomed Lublin Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 95. Biomed Lublin Tuberculosis Vaccine Treatment Product Offerings
  • Table 96. Biomed Lublin Recent Development
  • Table 97. Taj Pharmaceuticals Company Information
  • Table 98. Taj Pharmaceuticals Introduction and Business Overview
  • Table 99. Taj Pharmaceuticals Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 100. Taj Pharmaceuticals Tuberculosis Vaccine Treatment Product Offerings
  • Table 101. Taj Pharmaceuticals Recent Development
  • Table 102. Ataulpho de Paiva Company Information
  • Table 103. Ataulpho de Paiva Introduction and Business Overview
  • Table 104. Ataulpho de Paiva Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 105. Ataulpho de Paiva Tuberculosis Vaccine Treatment Product Offerings
  • Table 106. Ataulpho de Paiva Recent Development
  • Table 107. IVAC Company Information
  • Table 108. IVAC Introduction and Business Overview
  • Table 109. IVAC Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 110. IVAC Tuberculosis Vaccine Treatment Product Offerings
  • Table 111. IVAC Recent Development
  • Table 112. Queen Saovabha Mem. Inst Company Information
  • Table 113. Queen Saovabha Mem. Inst Introduction and Business Overview
  • Table 114. Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 115. Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Product Offerings
  • Table 116. Queen Saovabha Mem. Inst Recent Development
  • Table 117. Microgen Company Information
  • Table 118. Microgen Introduction and Business Overview
  • Table 119. Microgen Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US$ Million), Price (USD/K Dose) and Gross Margin (2020-2025)
  • Table 120. Microgen Tuberculosis Vaccine Treatment Product Offerings
  • Table 121. Microgen Recent Development
  • Table 122. Key Raw Materials Lists
  • Table 123. Raw Materials Key Suppliers Lists
  • Table 124. Tuberculosis Vaccine Treatment Downstream Customers
  • Table 125. Tuberculosis Vaccine Treatment Distributors List
  • Table 126. Research Programs/Design for This Report
  • Table 127. Key Data Information from Secondary Sources
  • Table 128. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Tuberculosis Vaccine Treatment Product Picture
  • Figure 2. Global Tuberculosis Vaccine Treatment Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Tuberculosis Vaccine Treatment Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Tuberculosis Vaccine Treatment Sales Volume (2020-2031) & (K Dose)
  • Figure 5. Global Tuberculosis Vaccine Treatment Sales Price (2020-2031) & (USD/K Dose)
  • Figure 6. Tuberculosis Vaccine Treatment Report Years Considered
  • Figure 7. Global Tuberculosis Vaccine Treatment Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Tuberculosis Vaccine Treatment Players Sales Volume Ranking (2024) & (K Dose)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Tuberculosis Vaccine Treatment Revenue in 2024
  • Figure 10. Tuberculosis Vaccine Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Immune Vaccine Picture
  • Figure 12. Therapy Vaccine Picture
  • Figure 13. Global Tuberculosis Vaccine Treatment Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Tuberculosis Vaccine Treatment Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Tuberculosis Vaccine Treatment Sales Volume by Type (2020 VS 2024 VS 2031) & (K Dose)
  • Figure 16. Global Tuberculosis Vaccine Treatment Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global Tuberculosis Vaccine Treatment Price by Type (2020-2031) & (USD/K Dose)
  • Figure 18. Product Picture of Self-Procurement
  • Figure 19. Product Picture of UNICEF
  • Figure 20. Product Picture of Other
  • Figure 21. Global Tuberculosis Vaccine Treatment Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 22. Global Tuberculosis Vaccine Treatment Sales Value Market Share by Application, 2024 & 2031
  • Figure 23. Global Tuberculosis Vaccine Treatment Sales Volume by Application (2020 VS 2024 VS 2031) & (K Dose)
  • Figure 24. Global Tuberculosis Vaccine Treatment Sales Volume Market Share by Application, 2024 & 2031
  • Figure 25. Global Tuberculosis Vaccine Treatment Price by Application (2020-2031) & (USD/K Dose)
  • Figure 26. North America Tuberculosis Vaccine Treatment Sales Value (2020-2031) & (US$ Million)
  • Figure 27. North America Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Europe Tuberculosis Vaccine Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Europe Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Asia Pacific Tuberculosis Vaccine Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Asia Pacific Tuberculosis Vaccine Treatment Sales Value by Region (%), 2024 VS 2031
  • Figure 32. South America Tuberculosis Vaccine Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. South America Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Middle East & Africa Tuberculosis Vaccine Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Middle East & Africa Tuberculosis Vaccine Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 36. Key Countries/Regions Tuberculosis Vaccine Treatment Sales Value (%), (2020-2031)
  • Figure 37. Key Countries/Regions Tuberculosis Vaccine Treatment Sales Volume (%), (2020-2031)
  • Figure 38. United States Tuberculosis Vaccine Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. United States Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 40. United States Tuberculosis Vaccine Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 41. Europe Tuberculosis Vaccine Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. Europe Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 43. Europe Tuberculosis Vaccine Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 44. China Tuberculosis Vaccine Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. China Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 46. China Tuberculosis Vaccine Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 47. Japan Tuberculosis Vaccine Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. Japan Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 49. Japan Tuberculosis Vaccine Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 50. South Korea Tuberculosis Vaccine Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 51. South Korea Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 52. South Korea Tuberculosis Vaccine Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 53. Southeast Asia Tuberculosis Vaccine Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 54. Southeast Asia Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 55. Southeast Asia Tuberculosis Vaccine Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 56. India Tuberculosis Vaccine Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 57. India Tuberculosis Vaccine Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 58. India Tuberculosis Vaccine Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 59. Tuberculosis Vaccine Treatment Industrial Chain
  • Figure 60. Tuberculosis Vaccine Treatment Manufacturing Cost Structure
  • Figure 61. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 62. Bottom-up and Top-down Approaches for This Report
  • Figure 63. Data Triangulation
  • Figure 64. Key Executives Interviewed